Sylvest Advisors LLC Makes New $835,000 Investment in Bristol Myers Squibb Company $BMY

Sylvest Advisors LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 13,769 shares of the biopharmaceutical company’s stock, valued at approximately $835,000. Bristol Myers Squibb comprises 0.4% of Sylvest Advisors LLC’s holdings, making the stock its 26th largest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BMY shares. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Bank of America dropped their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. HSBC upped their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $61.31.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $57.45 on Friday. The company has a market cap of $117.31 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock’s fifty day moving average price is $57.06 and its 200 day moving average price is $57.27. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the previous year, the business earned $1.80 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.